Payment overview · 2025
General Payments
$226.80
12 reported records · 7 companies
Healthcare provider profile · identity verified
Emad Jacob, MD
Allopathic & Osteopathic Physicians|Internal Medicine · KEARNEY, NJ · NPI 1669622015
Verified facts
What the public records show
CMS Open Payments records show Emad Jacob, MD received $226.80 in general payments during 2025 across 12 reported records.
Novo Nordisk Inc accounted for 26.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ubrelvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 184 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 278 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $60.19 | 26.5% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $46.42 | 20.5% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $35.70 | 15.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.72 | 13.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.00 | 8.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.13 | 8.0% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $16.64 | 7.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $226.80 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $46.42 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $39.51 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $35.70 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $30.72 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.72 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.68 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.13 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $16.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 278 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 184 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
66 | 21 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
75 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
184 | 33 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
87 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
23 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
278 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
23 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1106 | 272 |
| Amlodipine Besylate | Amlodipine Besylate | 834 | 211 |
| Losartan Potassium | Losartan Potassium | 645 | 174 |
| Metformin Hcl | Metformin Hcl | 645 | 146 |
| Levothyroxine Sodium | Levothyroxine Sodium | 555 | 118 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 394 | 125 |
| Gabapentin | Gabapentin | 383 | 99 |
| Fluticasone Propionate | Fluticasone Propionate | 365 | 186 |
| Metoprolol Succinate | Metoprolol Succinate | 344 | 80 |
| Omeprazole | Omeprazole | 341 | 143 |
| Pantoprazole Sodium | Pantoprazole Sodium | 325 | 73 |
| Lisinopril | Lisinopril | 287 | 77 |
| Furosemide | Furosemide | 284 | 57 |
| Eliquis | Apixaban | 278 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 263 | 65 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 257 | 78 |
| Mirtazapine | Mirtazapine | 256 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 235 | 52 |
| Jardiance | Empagliflozin | 234 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 224 | 56 |
| Escitalopram Oxalate | Escitalopram Oxalate | 220 | 34 |
| Farxiga | Dapagliflozin Propanediol | 213 | 39 |
| Carvedilol | Carvedilol | 188 | 42 |
| Alendronate Sodium | Alendronate Sodium | 185 | 50 |
| Ozempic | Semaglutide | 184 | 33 |
| Metformin Hcl Er | Metformin Hcl | 177 | 55 |
| Januvia | Sitagliptin Phosphate | 170 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 169 | 44 |
| Simvastatin | Simvastatin | 169 | 43 |
| Mounjaro | Tirzepatide | 166 | 24 |
| Meloxicam | Meloxicam | 163 | 111 |
| Memantine Hcl | Memantine Hcl | 156 | 20 |
| Enalapril Maleate | Enalapril Maleate | 154 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 153 | 33 |
| Donepezil Hcl | Donepezil Hcl | 150 | 21 |
| Trazodone Hcl | Trazodone Hcl | 146 | 23 |
| Potassium Chloride | Potassium Chloride | 143 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 134 | 60 |
| Allopurinol | Allopurinol | 126 | 33 |
| Sertraline Hcl | Sertraline Hcl | 126 | 18 |
| Divalproex Sodium | Divalproex Sodium | 125 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 124 | 11 |
| Insulin Lispro | Insulin Lispro | 107 | 16 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 107 | 16 |
| Famotidine | Famotidine | 91 | 27 |
| Hydralazine Hcl | Hydralazine Hcl | 88 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 88 | 26 |
| Rybelsus | Semaglutide | 87 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 83 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 81 | 24 |
| Montelukast Sodium | Montelukast Sodium | 80 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 75 | 19 |
| Enoxaparin Sodium | Enoxaparin Sodium | 71 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 71 | 15 |
| Latanoprost | Latanoprost | 71 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 67 | 52 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 66 | suppressed |
| Linzess | Linaclotide | 66 | 21 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 65 | 15 |
| Lactulose | Lactulose | 64 | 24 |
| Xarelto | Rivaroxaban | 64 | suppressed |
| Levetiracetam | Levetiracetam | 62 | 11 |
| Azithromycin | Azithromycin | 61 | 58 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 60 | 39 |
| Ezetimibe | Ezetimibe | 59 | 23 |
| Finasteride | Finasteride | 58 | 13 |
| Hydrocortisone | Hydrocortisone | 58 | 36 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 57 | 18 |
| Naproxen | Naproxen | 57 | 43 |
| Sucralfate | Sucralfate | 55 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 54 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 53 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 52 | 19 |
| Glimepiride | Glimepiride | 52 | 14 |
| Ibuprofen | Ibuprofen | 50 | 23 |
| Risperidone | Risperidone | 50 | suppressed |
| Spironolactone | Spironolactone | 50 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 49 | 17 |
| Tradjenta | Linagliptin | 49 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 48 | 13 |
| Chlorthalidone | Chlorthalidone | 47 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 47 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 45 | suppressed |
| Atenolol | Atenolol | 44 | suppressed |
| Gemfibrozil | Gemfibrozil | 44 | 16 |
| Lidocaine | Lidocaine | 44 | 16 |
| Nebivolol Hcl | Nebivolol Hcl | 44 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 44 | 38 |
| Pravastatin Sodium | Pravastatin Sodium | 44 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 44 | 37 |
| Amoxicillin | Amoxicillin | 43 | 38 |
| Amitriptyline Hcl | Amitriptyline Hcl | 41 | 11 |
| Myrbetriq | Mirabegron | 41 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 40 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 39 | 35 |
| Telmisartan | Telmisartan | 39 | 11 |
| Promethazine Hcl | Promethazine Hcl | 37 | 26 |
| Vascepa | Icosapent Ethyl | 37 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 36 | 17 |
| Ketoconazole | Ketoconazole | 35 | 12 |
| Nifedipine Er | Nifedipine | 35 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | 13 |
| Irbesartan | Irbesartan | 34 | 12 |
| Trulicity | Dulaglutide | 34 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 33 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 32 | suppressed |
| Levocarnitine | Levocarnitine | 32 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 21 |
| Glipizide | Glipizide | 31 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 31 | 25 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 31 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 30 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 30 | suppressed |
| Nystatin | Nystatin | 30 | 13 |
| Clonidine Hcl | Clonidine Hcl | 29 | 11 |
| Folic Acid | Folic Acid | 29 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 28 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 27 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 17 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 26 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 26 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 21 |
| Dutasteride | Dutasteride | 25 | suppressed |
| Glipizide Er | Glipizide | 25 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 25 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 25 | suppressed |
| Olanzapine | Olanzapine | 25 | suppressed |
| Prednisone | Prednisone | 25 | 17 |
| Primidone | Primidone | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Timolol Maleate | Timolol Maleate | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 23 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 19 |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 17 |
| Ursodiol | Ursodiol | 22 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 21 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 21 | suppressed |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 21 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 20 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 19 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 19 | 19 |
| Ramelteon | Ramelteon | 19 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Clonidine | Clonidine | 18 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 18 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 18 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 18 | suppressed |
| Sodium Polystyrene Sulfonate | Sodium Polystyrene Sulfonate | 18 | 15 |
| Sps | Sodium Polystyrene Sulfon/Sorb | 18 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 17 | 13 |
| Loperamide | Loperamide Hcl | 17 | 11 |
| Mometasone Furoate | Mometasone Furoate | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | 12 |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Phenytoin | Phenytoin | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 13 | 13 |
| Dextrose 5%-0.45% Nacl | Dextrose 5 %-0.45 % Sod Chlord | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Tivicay | Dolutegravir Sodium | 13 | suppressed |
| Tobradex | Tobramycin/Dexamethasone | 13 | suppressed |
| Ubrelvy | Ubrogepant | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | 11 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 12 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 12 | suppressed |
| Entacapone | Entacapone | 12 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 12 | suppressed |
| Juluca | Dolutegravir/Rilpivirine | 12 | suppressed |
| Nexium | Esomeprazole Magnesium | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Abacavir-Lamivudine | Abacavir Sulfate/Lamivudine | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 11 | suppressed |
| Repaglinide | Repaglinide | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $226.80 · 12 records | Novo Nordisk Inc | ELIQUIS, IBSRELA, Korlym, OTEZLA, Ozempic, REPATHA, SHINGRIX, UBRELVY, Wegovy | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error